Vitamin K Market Size, Share & Industry Analysis, By Type (K1 and K2), By Application (Osteoporosis, Vitamin K Dependent Clotting Factor Deficiency (VKCFD), Prothrombin Deficiency, Dermal Application, and Others), By Route of Administration ( Oral [Tablets/Pills, Powder, and Liquid], Parenteral, and Topical), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, Pharmacy Stores, Online Stores, and Others) and Regional Forecast, 2024-2032

Vitamin K is an essential vitamin occurring majorly in two forms, K-1 and K-2. Vitamin K helps the body in clotting and coagulating blood and maintaining bone health. Consumers are becoming increasingly aware of the importance of maintaining good health and are turning to dietary supplements to bridge the potential nutrition gaps. Moreover, vitamin K, with its established benefits for bone and cardiovascular health, is further attracting growing interest. The global rise in chronic diseases such as osteoporosis, blood clotting disorders, and diabetes is a major driver. Vitamin K plays a significant role in managing these conditions, leading to increased demand for preventive and therapeutic applications.

The growing popularity of functional foods and beverages fortified with vitamins and minerals creates an opportunity for vitamin K. Similarly, the focus on proper infant nutrition with vitamin K supplementation for preventing vitamin K deficiency bleeding (VKDB) in newborns is another growth factor driving the market growth. According to the National Center for Biotechnology Information, Vitamin K prophylaxis should occur within an hour of birth to prevent severe bleeding in infants.

Key Insights

The report covers the following key insights:

• Overview of the Vitamin K Market


• Supply Chain and Regulatory Analysis


• Drivers, Restraints, and Opportunities


• Impact of COVID-19 on the Global Vitamin K Market


• Key Developments

Segmentation

Analysis by Type

By type, the market is bifurcated into K1 and K2. The K2 segment is expected to hold a major share of the global market. Vitamin K2 is gaining traction due to its perceived wider range of health benefits compared to vitamin K1. According to the National Center for Biotechnology Information, vitamin K2, also known as menaquinone-7, possesses beneficial health benefits such as cardiovascular disease, osteoporosis, inflammation, Alzheimer’s disease, diabetes, and others. MK-7 is popular due to advances in its production through fermentation processes, making it more readily available in supplements. Manufacturers are also adopting several business strategies in order to meet the growing vitamin K demand.

For instance, in October 2020, Synergia Life Sciences, an ingredients manufacturer based in India, received a European patent for its vitamin K2 as a menaquinone-7 (MK-7) ingredient, MenaquinGold. The ingredient has a number of positive effects on cardiovascular health. The patent recognized the ingredient’s efficacy in ameliorating hypoxia in venous insufficiency, improving blood perfusion, treatment of post-thrombotic syndrome complications in human subjects and relieving symptoms of chronic venous insufficiency.

The K1 segment is expected to grow significantly over the forecast period. Vitamin K1, also known as phylloquinone, plays a crucial role in blood clotting. Deficiency can lead to bleeding complications. Food fortification with vitamin K1 is a growing trend, especially in products such as cereals and infant formulas, expanding the K1 reach beyond supplements and into everyday dietary sources.

Analysis by Application

By application, the market is segmented into osteoporosis, vitamin K dependent clotting factor deficiency (VKCFD), prothrombin deficiency,  dermal application, and others.

The osteoporosis segment holds the largest share of the global vitamin K market. Osteoporosis is a major public health concern, affecting millions globally, particularly postmenopausal women and elderly individuals. According to the U.S. Department of Health and Human Services, in the U.S. an estimated 10 million people age 50 years and older have osteoporosis. While there are other medications for osteoporosis, vitamin K offers a natural and well-tolerated approach, making it an attractive option for many consumers.

The vitamin K-dependent clotting factor deficiency segment is also expected to grow at a high CAGR over the forecast period. There is growing awareness of VKCFD among healthcare professionals, leading to more diagnose and identification of patients requiring treatment. Currently, there are limited treatment options for some forms of VKCFD, creating significant opportunities for the development and market launch of new therapies, driving market growth.

The application of vitamin K in dermal applications is also expected to have high growth in the coming future. Topical vitamin K creams are gaining traction for their potential to improve various skin concerns, including the healing of bruises, scars, and stretch marks, reduce the appearance of spider veins, reduce inflammation and others.

Analysis by Route of Administration

By route of administration, the market is divided into oral [tablets/pills, powder, and liquid], parenteral, and topical.

The oral segment is expected to hold a major share of the global market. Oral supplements in the form of tablets, capsules, pills, powders and liquid are more accessible and more convenient to take compared to injections (parenteral route) or topical applications. Moreover, oral formulations are generally less expensive to manufacturers and distribute, making them more affordable options for consumers and healthcare providers.

The topical segment is expected to grow significantly over the forecast period. Consumers might find topical applications easier to use or prefer localized effects. This could be especially true for conditions, such as skin ulcers or specific areas of concern.

Analysis by Distribution Channel

By distribution channel, the market is classified into (supermarkets/hypermarkets, convenience stores, pharmacy stores, online stores, and others.

The pharmacy stores segment is expected to hold a major share of the global market. Pharmacies offer a convenient and accessible channel for consumers to purchase vitamin K supplements. They often have a wide variety of brands and formulations to choose from, catering to different needs and preferences. Pharmacists also provide valuable advice and recommendations to consumers regarding vitamin K supplements. This guidance can be beneficial for individuals with specific health conditions or those unsure about the correct dosage.

The online stores segment is expected to grow significantly over the forecast period. Online stores offer an accessible way to order supplements such as vitamin K. They can browse a wide variety of products at any time and have them delivered to their doorstep.

Regional Analysis

To gain extensive insights into the market, Request for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

North America holds the largest share of the vitamin K market. The region has a well-established market for dietary supplements and fortified foods. Consumers are accustomed to incorporating these products into their health routines, creating a strong foundation for vitamin K products. North America boasts a high healthcare expenditure, with individuals willing to invest in preventive measures and treatments. This fuels the demand for vitamin K supplements and their use in managing diseases.

Europe is expected to grow significantly over the forecast period. Countries, such as Germany. France and the U.K. are expected to see significant growth in the vitamin K market owing to factors such as growing awareness of vitamin K, increasing disposable income, and a growing elderly population.

Key Players Covered

The report includes the profiles of the following key players: Kappa Bioscience, NattoPharma, Gnosis S.p.A., Koninklijke DSM N.V., Viridis BioPharma, Frutarom, DuPont Nutrition & Health, Synergia Life Sciences, and Mankind Pharma.

Key Industry Developments

• In March 2024, SunWay Biotech, a manufacturer of biotechnology products, partnered with  Gnosis by Lesaffre to develop a new ingredient, MenaQ7 Metabolic, which also features the former company’s Ankascin 568-R ingredient. The new product combines vitamin K2 as MK-7 and Ankascin 568-R, a red yeast rice fermentation material.


• In April 2023, Petrovax Pharm, one of the leading Russian manufacturers of immunobiological products and vaccines, launched its new product, SunDevit, in the Russian market. The new product contains a combination of vitamins D3 and K2.